On 20 August 2020, Shanghai Kehua Bio-Engineering Co., Ltd. (“KHB”, 002022.SZ) officially issued its convertible bonds amounting to RMB 738,000,000 on Shenzhen Stock Exchange.
Over the three decades since its foundation in 1981 has witnessed KHB’s development into a hi-tech company integrating R&D, manufacturing and marketing business operation covering the whole industrial chain of IVD sector. In 2004, it was listed in the SME Board of Shenzhen Stock Exchange. The fund so raised will be used to expand the business scale, and enhance operation efficiency and overall competitiveness as well.
Grandall Shanghai Office has been retained as the legal counsel for the project with Mr. WANG Weidong, Mr. ZHAO Zhenxing, Ms. DU Lishan and Ms. CHEN Huihui as key lawyers servicing the case.